The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma

Cancer Microenvironment - Tập 4 - Trang 13-21 - 2010
Magdalena Dutsch-Wicherek1, Agata Lazar2, Romana Tomaszewska2
1Otolaryngology Head and Neck Surgery Department, Jagiellonian University, Kraków, Poland
2Pathology Department, Jagiellonian University, Kraków, Poland

Tóm tắt

The tumor microenvironment is the tissue that determines the growth and progression of the tumor as well as its ability to initiate metastases. The aim of the present study has been to evaluate the role of RCAS1 in creating the suppressive tumor microenvironment in cases of parotid adenocarcinoma. The tissue samples of salivary gland adenocarcinomas and their stroma and the palatine tonsils which constituted the reference tissue sample group were obtained during routine surgical procedures. The immunoreactivity of RCAS1, CD3, CD25, CD68, CD69, and Foxp3 antigens was then evaluated by using the immunohistochemistry method. The patient’s consent was obtained in each case. A statistically significantly higher RCAS1 immunoreactivity level was found in the adenocarcinoma tissue samples in comparison to that found in the stromal tissue samples. A statistically significantly higher RCAS1 immunoreactivity was also identified in the adenocarcinoma tissue samples derived from patients who had lymph node metastases in comparison to patients without such metastases. Additionally, we observed the presence of RCAS1-positive macrophages in the stromal tissue samples. The infiltration of CD68-positive cells was significantly stronger in the adenocarcinoma and stromal tissue slides than in the reference group tissue slides; moreover, the infiltration was a good deal more prominent in the stromal tissue than in the adenocarcinoma tissue. The CD68 immunoreactivity levels in both the tumor and stromal tissue samples were found to be significantly higher in those patients who had lymph node metastases than in the patients without such metastases. Additionally, the infiltration of CD3- and CD25-positive cells was more prominent in the reference tissue slides than in the adenocarcinoma and stromal tissue slides, and was stronger in the adenocarcinoma tissue than in the stromal tissue. Furthermore, the infiltration of Foxp3-positive cells was seen exclusively in the stroma whereas it was not even detected in the adenocarcinoma tissue. Lastly, the Foxp3-positive cell infiltration was more prominent in the stromal tissue than in the reference group tissue. The present study demonstrates that RCAS1 expression by both tumor cells and tumor-associated macrophages may participate in creating the immunosuppressive microenvironment in parotid gland adenocarcinoma, thus promoting tumor development as well as metastases.

Tài liệu tham khảo

Witz IP (2009) The tumor microenvironment: the making of a paradigm. Cancer Microenvironment 2:S9–S17 Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curie T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W (2007) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. JEM 203:871–881 Zou W (2005) Immunosuppressive networks in the tumor microenvironment and their therapeutic relevance. Nat Rev Cancer 5:263–274 Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867 Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T (1996) A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 77:1501–1509 Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H (2006) Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol Oncol 103:924–931 Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H (2005) Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol Oncol 99:189–198 Sonoda K, Miyamoto S, Kobayashi H, Ogawa S, Okugawa K, Taniguchi S, Wake N (2009) The level of RCAS1 expression is inversely correlated with the number of vimentin-positive stromal cells in epithelial ovarian cancer. Int J Gynecol Cancer 19:838–843 Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer — observations in vitro and in vivo. Cells Tissues Organs 185:191–203 Dutsch-Wicherek M, Tomaszewska R, Lazar A, Wicherek Ł, Skladzień J (2009) The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse. BMC Cancer 9:35 Dutsch-Wicherek M (2010) RCAS1, MT, and vimentin as potential markers of tumor microenvironment remodeling. Am J Reprod Immunol 63:181–188 Tsujitani S, Saito H, Oka S, Sakamoto T, Kanaji S, Tatebe S, Ikeguchi M (2002) Prognostic significance of RCAS1 expression in relation to the infiltration of dendritic cells and lymphocytes in patients with esophageal carcinoma. Dig Dis Sci 52:549–554 Fukuda K, Tsujitani S, Maeta Y, Yamaguchi K, Ikeguchi M, Kaibara N (2002) The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer 5:220–227 Nakamura Y, Yamazaki K, Oizumi S, Nakashima M, Watanabe T, Dosaka-Akita H, Nishimura M (2004) Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci 95:260–265 Oshikiri T, Hida Y, Miyamoto M, Hashida H, Katoh K, Suzuoki M, Nakakubo Y, Hiraoka K, Shinohara T, Itoh T, Kondo S, Katoh H (2001) RCAS1 as a tumor progression marker: an independent negative prognostic factor in gallbladder cancer. Br J Cancer 85:1922–1927 Hiraoka K, Hida Y, Miyamoto M, Oshikiri T, Suzuoki M, Nakakubo Y, Shinohara T, Itoh T, Shichinohe T, Kondo S, Kasahara N, Katoh H (2002) High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 99:418–423 Okada T, Iiai T, Kawachi Y, Moroda T, Takii Y, Hatakeyama K, Abo T (1995) Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol 102:159–166 Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444 Sonoda K, Miyamoto S, Yotsumoto F, Yagi H, Nakashima M, Watanabe T, Nakano H (2007) Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol Rep 17:623–628 Dutsch-Wicherek M, Wicherek L (2008) The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am J Reprod Immunol 59:266–275 Wicherek Ł, Dutsch M, Mak P, Klimek M, Skladzien J, Dubin A (2003) Comparative analysis of RCAS1 level in neoplasms and placenta. Acta Biochim Pol 50:1187–1194 Akashi T, Oimomi H, Nishiyama K, Nakashima M, Arita Y, Sumii T, Kimura T, Ito T, Nawata H, Watanabe T (2003) Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas 26:49–55 Wicherek L (2009) Alterations in RCAS1 serum concentration levels during menstrual cycle in patients with uterine leiomyoma and lack of analogical changes in adenomyosis. Gynecol Obstet Investig 67:195–201 Coban S, Ozkan H, Köklü S, Yüksel O, Koçkar MC, Akar T, Ormeci N (2006) The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can J Gastroenterol 20:593–596 Waldmann TA (1993) The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 14:264–270 Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M (1994) Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275–1282 Parmiani G, Anichini A, Fossati G (1990) Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 82:361–370 Parmiani G (1990) An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol Today 11:113–115 Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM (1996) Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J Immunol 156:3486–3492 Miescher S, Whiteside TL, Moretta L, Von Fliedner V (1987) Clonal and frequency analyses of tumor infiltrating T lymphocytes from human solid tumors. J Immunol 138:4004–4011 Sheu BC, Lin RH, Ho HN, Huang SC (1997) Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. Hum Immunol 56:39–48 Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022–7029 Pollard JW (2004) Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 4:71–78 Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumor growth. Nat Rev Immunol 4:641–648 Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–555 Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25:315–322 Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A (1983) Regulation of the macrophage content of neoplasms by chemoattractans. Science 220:210–212 Polverini P, Leibovich SJ (1984) Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 51:635–642 Suehiro Y, Muta K, Nakashima M, Abe Y, Shiratsuchi M, Shiokawa S, Ikuyama S, Yoshikawa Y, Watanabe T, Nishimura J (2005) A novel mechanism in suppression of erythropoiesis during inflammation: a crucial role of RCAS1. Eur J Haematol 74:365–373 Matsushima T, Nakashima M, Oshima K, Abe Y, Nishimura J, Nawata H, Watanabe T, Muta K (2001) Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood 15:313–321 Enjoji M (2006) RCAS1-expressing macrophages in inflammatory liver diseases. Liver Int 26:385–387 Dutsch-Wicherek M, Tomaszewska R, Stręk P, Wicherek Ł, Składzień J (2006) The analysis of RCAS1 and DFF-45 expression in nasal polyps with respect to immune cells infiltration. BMC Immunol 7:4 Dutsch-Wicherek M, Tomaszewska R, Lazar A, Strek P, Wicherek Ł, Piekutowski K, Jóźwicki W (2010) The evaluation of metallothionein expression in nasal polyps with respect to immune cell presence and activity. BMC Immunol 11:10 Whiteside TL (2010) Immune responses to malignancies. J Allergy Clin Immunol 125:S272–S283 Knutson KL, Disis ML, Salazar LG (2007) CD4 regulatory cells in human cancer pathogenesis. Cancer Immunol Immunother 56:271–285